Literature DB >> 16770036

Intravitreal injection of triamcinolone acetonide for diabetic macular edema: principles and practice.

Vasumathy Vedantham1, Ramasamy Kim.   

Abstract

Diabetic retinopathy is fast emerging as a leading cause of newly diagnosed legal blindness amongst the working population. Macular edema, as it is commoner, accounts for more vision impairment than neovascular proliferation in diabetic patients. Laser photocoagulation, which is the standard treatment of macular edema, is associated with significant complications and an improvement in visual acuity is unsatisfactory. Intravitreal injection of corticosteroids (especially triamcinolone acetonide) is an emerging treatment modality in the management of diabetic macular edema. This article presents an overview of the principles, technique and complications associated with this procedure.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16770036     DOI: 10.4103/0301-4738.25840

Source DB:  PubMed          Journal:  Indian J Ophthalmol        ISSN: 0301-4738            Impact factor:   1.848


  3 in total

1.  Melt-Cast Films Significantly Enhance Triamcinolone Acetonide Delivery to the Deeper Ocular Tissues.

Authors:  Akshaya Tatke; Narendar Dudhipala; Karthik Yadav Janga; Bhavik Soneta; Bharathi Avula; Soumyajit Majumdar
Journal:  Pharmaceutics       Date:  2019-04-02       Impact factor: 6.321

Review 2.  Use of intravitreal injection of triamcinolone acetonide in the treatment of age-related macular degeneration.

Authors:  Lekha Gopal; Tarun Sharma
Journal:  Indian J Ophthalmol       Date:  2007 Nov-Dec       Impact factor: 1.848

3.  Intravitreal bevacizumab (Avastin) treatment of diffuse diabetic macular edema in an Indian population.

Authors:  Atul Kumar; Subijay Sinha
Journal:  Indian J Ophthalmol       Date:  2007 Nov-Dec       Impact factor: 1.848

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.